Jefferies Maintains Buy on Nurix Therapeutics, Raises Price Target to $45
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Roger Song maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $41 to $45.
Jefferies analyst Roger Song maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $41 to $45.